Oral contraceptives and thrombosis

Area of Science:

• Pharmacology
• Thrombosis Research
• Public Health

Background:

• Oral contraceptives (OCs) are widely used by young women for pregnancy prevention.
• Despite formulation advancements, OCs are linked to an elevated risk of venous thromboembolism (VTE).
• Concerns exist regarding third-generation OCs potentially increasing thrombotic risks compared to second-generation formulations.

Purpose of the Study:

• To evaluate the association between oral contraceptive use and venous thromboembolism (VTE).
• To discuss the societal and medical implications of VTE risk relative to OC benefits.
• To explore the potential mechanisms behind increased VTE risk with newer OC generations.

Main Methods:

• Review of case-control and prospective studies on OC use and VTE.
• Analysis of relative risk data for VTE associated with different OC generations.
• Discussion of potential biological mechanisms, such as activated protein C resistance.

Main Results:

• Oral contraceptives are definitively associated with an increased risk of venous thromboembolism (VTE).
• Third-generation OCs may present a higher thrombotic risk than second-generation OCs.
• Activated protein C resistance is a potential explanation for increased VTE risk with altered progestogen content.

Conclusions:

• The risk of VTE associated with oral contraceptives requires careful consideration against their benefits.
• Patient selection and screening for hypercoagulability markers may help mitigate VTE risk.
• Further attention to patient selection is recommended given societal intolerance to medication side effects.